These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
421 related articles for article (PubMed ID: 30345010)
21. Management of gallstones and its related complications. Portincasa P; Di Ciaula A; de Bari O; Garruti G; Palmieri VO; Wang DQ Expert Rev Gastroenterol Hepatol; 2016; 10(1):93-112. PubMed ID: 26560258 [TBL] [Abstract][Full Text] [Related]
22. [Innovations in the medical treatment of gallstones and fatty liver: FABACs (Fatty Acid Bile Acid Conjugates)]. Keizman D; Goldiner I; Leikin-Frenkel A; Konikoff FM Harefuah; 2008 Apr; 147(4):344-9, 373, 372. PubMed ID: 18686819 [TBL] [Abstract][Full Text] [Related]
23. Hereditary liver disease: gallstones. Wittenburg H Best Pract Res Clin Gastroenterol; 2010 Oct; 24(5):747-56. PubMed ID: 20955975 [TBL] [Abstract][Full Text] [Related]
24. Effect of Inhibition of Intestinal Cholesterol Absorption on the Prevention of Cholesterol Gallstone Formation. Portincasa P; Wang DQ Med Chem; 2017; 13(5):421-429. PubMed ID: 28185534 [TBL] [Abstract][Full Text] [Related]
25. Prevention of gallbladder hypomotility via FATP2 inhibition protects from lithogenic diet-induced cholelithiasis. Tharp KM; Khalifeh-Soltani A; Park HM; Yurek DA; Falcon A; Wong L; Feng R; Atabai K; Stahl A Am J Physiol Gastrointest Liver Physiol; 2016 May; 310(10):G855-64. PubMed ID: 27033116 [TBL] [Abstract][Full Text] [Related]
26. Relation of gallbladder motility to viscosity and composition of gallbladder bile in patients with cholesterol gallstones. Gründel D; Jüngst C; Straub G; Althaus R; Schneider B; Spelsberg FW; Hüttl TP; del Pozo R; Jüngst D; Neubrand M Digestion; 2009; 79(4):229-34. PubMed ID: 19390195 [TBL] [Abstract][Full Text] [Related]
27. Therapy of gallstone disease: What it was, what it is, what it will be. Portincasa P; Ciaula AD; Bonfrate L; Wang DQ World J Gastrointest Pharmacol Ther; 2012 Apr; 3(2):7-20. PubMed ID: 22577615 [TBL] [Abstract][Full Text] [Related]
28. The effect of loss of gallbladder function on biliary lipid composition in subjects with cholesterol gallstones. Redinger RN Gastroenterology; 1976 Sep; 71(3):470-4. PubMed ID: 950098 [TBL] [Abstract][Full Text] [Related]
29. Genetics of gallstone disease. Rebholz C; Krawczyk M; Lammert F Eur J Clin Invest; 2018 Jul; 48(7):e12935. PubMed ID: 29635711 [TBL] [Abstract][Full Text] [Related]
30. The cholecystokinin-1 receptor antagonist devazepide increases cholesterol cholelithogenesis in mice. Wang HH; Portincasa P; Wang DQ Eur J Clin Invest; 2016 Feb; 46(2):158-69. PubMed ID: 26683129 [TBL] [Abstract][Full Text] [Related]
31. Recent advances, novel targets and treatments for cholelithiasis; a narrative review. E S; Srikanth MS; Shreyas A; Desai S; Mehdi S; Gangadharappa HV; Suman ; Krishna KL Eur J Pharmacol; 2021 Oct; 908():174376. PubMed ID: 34303667 [TBL] [Abstract][Full Text] [Related]
32. Inflammation and a thickened mucus layer in mice with cholesterol gallstones. Rege RV; Prystowsky JB J Surg Res; 1998 Jan; 74(1):81-5. PubMed ID: 9536979 [TBL] [Abstract][Full Text] [Related]
33. Current development in the pathogenesis of gallstones. Tandon RK Trop Gastroenterol; 1990; 11(3):130-9. PubMed ID: 2267670 [TBL] [Abstract][Full Text] [Related]
34. Gallstones in patients with morbid obesity. Relationship to body weight, weight loss and gallbladder bile cholesterol solubility. Shiffman ML; Sugerman HJ; Kellum JH; Brewer WH; Moore EW Int J Obes Relat Metab Disord; 1993 Mar; 17(3):153-8. PubMed ID: 8385075 [TBL] [Abstract][Full Text] [Related]
35. Ursodeoxycholic acid reduces lipid peroxidation and mucin secretagogue activity in gallbladder bile of patients with cholesterol gallstones. Jüngst C; Sreejayan N; Zündt B; Müller I; Spelsberg FW; Hüttl TP; Kullak-Ublick GA; del Pozo R; Jüngst D; von Ritter C Eur J Clin Invest; 2008 Sep; 38(9):634-9. PubMed ID: 18837739 [TBL] [Abstract][Full Text] [Related]